Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 5/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | IDH2 | P48735 | 1/20 | 0.42 |
| ▸ | BMP1 | P13497 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144369 | 0.89 | ANPEP (0.50) | CAPN1BMP1 | |
| SCHEMBL4130510 | 0.84 | CAPN1 (0.47) | FPR2CAPN1IDH2CTSLCTSS | |
| SCHEMBL13872588 | 0.83 | CAPN1 (0.46) | FPR2CAPN1CTSLCTSS | |
| SCHEMBL4133234 | 0.83 | CAPN1 (0.46) | FPR2CAPN1IDH2 | |
| SCHEMBL4128693 | 0.82 | CAPN1 (0.46) | FPR2CAPN1 | |
| SCHEMBL4129008 | 0.82 | TRPV4 (0.57) | CAPN1CTSSCTSK | |
| SCHEMBL14605638 | 0.82 | CAPN1 (0.46) | FPR2CAPN1 | |
| SCHEMBL5435388 | 0.81 | TRPV4 (0.57) | CAPN1CTSSCTSK | |
| SCHEMBL4140628 | 0.80 | TP53 (0.35) | FPR2TP53IDH2 | |
| SCHEMBL4140623 | 0.80 | TP53 (0.35) | FPR2TP53IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | claimed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| WO-2007030761-A2 | ACYCLIC 1,4-DIAMINES AND USES THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | FPR2 223/4885CAPN1 2031/4885TP53 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.